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of completion of radiotherapy in both study arm and placebo 
arm and reported. 2 patients progressed during therapy and 
were not included in analyses and two patients discontinued 
the intervention. A per protocol analyses was done. 
 
 
Results: At analysis there were 50 patients in each arm. The 
severity of clinical proctitis was found to be similar in both 
groups of patients with 12.2 % of patients experiencing 
toxicity of grade 2 and above in digestible starch group 
versus 14.6% in the resistant starch group. Functional 
proctitis was similarly graded and it was found that 16.3 % 
patients in digestible starch group experienced toxicity 
against 10.2 % patients in the amylase resistant starch group. 
This difference was seen at 4th week and continued in the 
subsequent weeks till the end of radiation. Both groups had 
similar reported toxicity at 6 weeks post intervention. Both 
groups were also found to have similar incidence of grade 2 
and above diarrhea. The non-digestible starch group was 
found to have 8% incidence as compared to 2% in the other 
group at the 5th and 6th week. The short chain fatty acid 
concentrations were found to be not significantly different in 
the groups at any point. 
 
 
Conclusion: The study failed to demonstrate a benefit in 
administration of resistant starch in excess of normal diet to 
patients receiving pelvic radiotherapy. This may be 
postulated to be due to concurrent use of chemotherapy and 
decrease in intestinal probiotics. 
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Purpose or Objective: To compare treatment outcomes in 
locally advanced cervical carcinoma (LACC) patients treated 
with neoadjuvant chemoradiation followed by radical surgery 
(surgery group: SG) versus radical chemoradiation plus 
brachytherapy boost (control group: CG). Results in terms of 
local control (LC), metastases-free survival (MFS), disease 
free survival (DFS) and overall survival (OS) were compared. 
 
Material and Methods: Seventy-six patients with LACC (SG) 
were matched to 76 patients (CG) with respect to age, 
histology and stage. Matching was performed without 
knowledge of outcomes. Patients characteristics are 
summarized in Table 1. The median FU was 35 months 
(range: 2-107) for SG and 29 months (range: 1-125) for CG, 
respectively. 
 
 
Results: At univariate analysis no significant differences 
between the two groups were recorded. Two-year and 5-year 
LC were 77.6% and 71.0% for SG and 76.1% and 70.3% for CG 
(p=0.8), respectively. Two-year and 5-year MFS were 79.3% 
and 70.8% for SG and 78.8% and 78.8% for CG (p=0.6), 
respectively. Two-year and 5-year DFS were 71.9% and 61.6% 
for SG and 66.1% and 61.0% for CG (p=0.8), respectively. 
Two-year and 5-year OS were 90.9% and 84.4% for SG and 
90.3% and 69.9% for CG (p=0.4), respectively. 
 
Conclusion: The two treatment approaches achieved 
comparable outcomes in patients with locally advanced 
cervical carcinoma. Further analyses are needed to compare 
the toxicity profile of these two treatment strategies. 
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MR-PET is an advanced hybrid imaging method giving both 
structural, functional, molecular and biochemical information 
simultaneously or almost simultaneously. There are still 
challenges, not only with the attenuation correction, but also 
with performance of the examination and timing of the MR 
and PET acquisition.  
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It is well known that MR data contains detailed information 
with high tissue contrast and that PET imaging gives 
molecular/biochemical information with high molecular 
sensitivity but what is the added value? A major goal with 
treatment planning is to delineate the tumor volume, which 
can be done with both MR and PET, but since the both 
modalities show different characteristics of the tumor the 
volume might differ between them. Challenges from the 
imaging point of view will be discussed. The availability to 
PET/CT is much higher and the challenges with this method 
are fewer. Some comparison of the two hybrid modalities will 
be done. The majority of PET studies are done with the 
tracer fluorodexyglucose, FDG, but beyond FDG a large 
number of tracer are available, all giving information about 
different biochemical properties of the tumor. A few of these 
tracers will be presented and discussed. 
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Purpose: To investigate the value of combined PET/MR 
imaging for biologically individualized radiotherapy (RT) 
planning.  
 
Methods: Hybrid PET/MR imaging offers the possibility to 
combine molecular information from PET with high resolution 
anatomical MR imaging. Consequently, a combination of the 
two different imaging data sets seems promising for improved 
automatic target volume delineation (TVD). An automatic co-
segmentation algorithm has been developed in our institution 
which derives probabilities of tumor presence by combining 
PET and MR data. Finally, the PET/MR-based probability maps 
are segmented to generate RT target volumes. Automatically 
segmented target volumes were compared to manual 
delineations from three experienced radiation oncologists.  
Furthermore, combined PET/MR imaging allows to assess PET 
and functional MR data at the same time. In the context of a 
clinical study, diffusion weighted (DW) as well as dynamic 
contrast enhanced (DCE) MRI were acquired in addition to 
anatomical images as well as FMISO and FDG PET images. 
Pairwise correlations of the different functional parameters 
were calculated in order to analyze for redundancy or 
complementarity respectively.  
 
Results: Automatic co-segmentation of tumor volumes based 
on combined FDG PET/MR imaging in head and neck cancer 
revealed robust and reproducible contours. The comparison 
of automatic and manual target volumes showed good 
agreement in terms of volume overlap. Deviation of the 
automatic compared to the manual contours was in the same 
order of magnitude as inter-observer variation. Compared to 
PET-based TVD, additional information from high resolution 
MR data improves automatic segmentation.  
A pairwise correlation analysis of parameters derived from 
FMISO PET, FDG PET, DW- and DCE-MRI on a voxel-level did 
only show moderate to low correlation coefficients hinting at 
a complementarity of the different investigated imaging 
methods. However, large inter-patient variations in terms of 
pairwise parameter correlations were observed.  
 
Conclusion: Functional and molecular imaging with combined 
PET/MR has the potential to improve TVD. At the same time, 
PET/MR allows to assess different levels of biological 
information which may in the future be important to derive 
individualized measures of radiation sensitivity. As a 
consequence, PET/MR imaging opens new doors for 
personalized RT planning and delivery in the near future. 
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Imaging is fundamentally important in modern radiotherapy. 
For several of the most common diagnoses both PET and MR 
provide important information in the clinical decision making 
at the radiotherapy department. The combination of PET and 
MR in integrated PET/MR scanners could be the most efficient 
imaging modality for these patients. PET/MR has however 
primarily been designed for diagnostics and adjustments are 
needed to enable effective use in radiotherapy. This includes 
for example the ability to image the patient in treatment 
position, the ability to account for immobilization devices in 
the attenuation correction, and the development of adequate 
quality assurance methods.  
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Purpose or Objective: Nitroglycerin is a nitric oxide donor 
being investigated because of its potential to increase 
tumour oxygenation. In phase II trial NCT01210378 
nitroglycerin is added to radical radiotherapy in patients with 
NSCLC stage IB-IV. Using a dedicated hypoxia PET tracer 
([18F]HX4; ref: Dubois et al, Proc Natl Acad Sci USA.2011) we 
investigate the effect of nitroglycerin on tumour hypoxia. 
Here, we report the results of the first 14 patients that 
completed the hypoxia scanning program. 
 
Material and Methods: A baseline [18F]HX4 PET scan (4h p.i.) 
was performed to measure hypoxia in the primary tumour 
and nodes. At least 48 hours later, a second [18F]HX4 PET 
scan was taken after application of a nitroglycerin patch 
(Transiderm nitro 5 mg). Between the two scans, patients did 
not receive any treatment. The primary tumour and involved 
nodes were defined on the planning FDG-PET-CT scan and 
fused with the HX-4 scan for analysis. The tumour-to-blood 
ratio (TBR) of [18F]HX4 and the Hypoxic Fraction (HF; the 
fraction of the volume with a TBR >1.4) were calculated for 
all lesions. The Wilcoxon signed rank test was used to 
evaluate differences between scan time points. 
 
Results: In 14 patients, the median interval between the 
scans was 4.5 +/-2.1 days (range: 2-7days). Seven patients 
(50%) exhibited hypoxia (HX-4 TBR>1.4) in the primary 
tumour and 4 of 10 patients (40%) had nodal disease with an 
HX4 TBR>1.4 in the lymph nodes. In total 9/14 patients (64%) 
showed hypoxia at baseline in the primary tumour and/or the 
lymph nodes. The effect of nitroglycerin on HX-4 uptake in 
hypoxic lesions was as follows: in 8/11 volumes (72%) and in 
6/9 patients (66%) nitroglycerin administration resulted in a 
decrease of the TBR of HX-4. Also, the median HF decreased 
from 12.9% to 1.2% (p=0.029), corresponding to a decrease in 
the median hypoxic volume of 5.4 cc to 0.5 cc (p=0.033). In 
the 7 non-hypoxic tumours and 6 non-hypoxic nodal volumes 
present at baseline, nitroglycerin caused a decrease of the 
TBR of HX-4 in 5, an increase in 5 and no effect in 3 lesions. 
None of the non-hypoxic lesions became hypoxic (TBR >1.4) 
after administration of nitroglycerin. 
 
